BACKGROUND: Zeta-associated protein 70 (ZAP70) is a widely recognized prognostic factor in chronic lymphocytic leukemia, but mechanisms by which its higher expression leads to a poor outcome must still be fully explained. DESIGN AND METHODS: In an attempt to unveil unfavorable cellular properties linked to high ZAP70 expression, we used gene expression profiling to identify genes associated with disparities in B cells from chronic lymphocytic leukemia patients expressing high versus low ZAP70 mRNA, measured by quantitative real-time PCR. Two groups of 7 patients were compared, selected on the basis of either high or low ZAP70 mRNA expression. RESULTS: Twenty-seven genes were differentially expressed with an FDR<10%, and several genes were significant predictors of treatment-free survival (TFS) and/or overall survival; PDE8A and FCRL family genes (down-regulated in ZAP70(+) patients) could predict TFS and overall survival; ITGA4 mRNA (up-regulated in ZAP70(+) patients) could significantly predict overall survival. Importantly, gene set enrichment analysis revealed overrepresentation of adhesion/migration genes. We therefore investigated in vitro adhesion/migration capacity of chronic lymphocytic leukemia cells into a stromal microenvironment or in response to conditioned medium. We showed that ZAP70(+) cells had better adhesion/migration capacities and only ZAP70(+) patient cells responded to microenvironment contact by CXCR4 downregulation. CONCLUSIONS: We concluded that several prognostic factors are the reflection of microenvironment interactions and that the increased adhesion/migratory capacity of ZAP70(+) cells in their microenvironment can explain their better survival and thus the aggressiveness of the disease.
BACKGROUND:Zeta-associated protein 70 (ZAP70) is a widely recognized prognostic factor in chronic lymphocytic leukemia, but mechanisms by which its higher expression leads to a poor outcome must still be fully explained. DESIGN AND METHODS: In an attempt to unveil unfavorable cellular properties linked to high ZAP70 expression, we used gene expression profiling to identify genes associated with disparities in B cells from chronic lymphocytic leukemiapatients expressing high versus low ZAP70 mRNA, measured by quantitative real-time PCR. Two groups of 7 patients were compared, selected on the basis of either high or low ZAP70 mRNA expression. RESULTS: Twenty-seven genes were differentially expressed with an FDR<10%, and several genes were significant predictors of treatment-free survival (TFS) and/or overall survival; PDE8A and FCRL family genes (down-regulated in ZAP70(+) patients) could predict TFS and overall survival; ITGA4 mRNA (up-regulated in ZAP70(+) patients) could significantly predict overall survival. Importantly, gene set enrichment analysis revealed overrepresentation of adhesion/migration genes. We therefore investigated in vitro adhesion/migration capacity of chronic lymphocytic leukemia cells into a stromal microenvironment or in response to conditioned medium. We showed that ZAP70(+) cells had better adhesion/migration capacities and only ZAP70(+) patient cells responded to microenvironment contact by CXCR4 downregulation. CONCLUSIONS: We concluded that several prognostic factors are the reflection of microenvironment interactions and that the increased adhesion/migratory capacity of ZAP70(+) cells in their microenvironment can explain their better survival and thus the aggressiveness of the disease.
Authors: Sarah J Richardson; Christine Matthews; Mark A Catherwood; H Denis Alexander; B Sean Carey; Joanna Farrugia; Anne Gardiner; Sarah Mould; David Oscier; J Adrian Copplestone; Archibald G Prentice Journal: Blood Date: 2005-12-06 Impact factor: 22.113
Authors: P Ghia; P Circosta; C Scielzo; A Vallario; A Camporeale; L Granziero; F Caligaris-Cappio Journal: Curr Top Microbiol Immunol Date: 2005 Impact factor: 4.291
Authors: Götz R A Ehrhardt; Chuen-Miin Leu; Shuangyin Zhang; Güzide Aksu; Tanisha Jackson; Chris Haga; Joyce T Hsu; Daniel M Schreeder; Randall S Davis; Max D Cooper Journal: Adv Exp Med Biol Date: 2007 Impact factor: 2.622
Authors: A Hüttmann; L Klein-Hitpass; J Thomale; R Deenen; A Carpinteiro; H Nückel; P Ebeling; A Führer; J Edelmann; L Sellmann; U Dührsen; J Dürig Journal: Leukemia Date: 2006-08-17 Impact factor: 11.528
Authors: Maria Ilaria Del Principe; Giovanni Del Poeta; Francesco Buccisano; Luca Maurillo; Adriano Venditti; Antonella Zucchetto; Rita Marini; Pasquale Niscola; Maria Antonietta Irno Consalvo; Carla Mazzone; Licia Ottaviani; Paola Panetta; Antonio Bruno; Riccardo Bomben; Giovanna Suppo; Massimo Degan; Valter Gattei; Paolo de Fabritiis; Maria Cantonetti; Francesco Lo Coco; Domenico Del Principe; Sergio Amadori Journal: Blood Date: 2006-04-06 Impact factor: 22.113
Authors: D Heintel; D Kienle; M Shehata; A Kröber; E Kroemer; I Schwarzinger; D Mitteregger; T Le; A Gleiss; C Mannhalter; A Chott; J Schwarzmeier; C Fonatsch; A Gaiger; H Döhner; S Stilgenbauer; U Jäger Journal: Leukemia Date: 2005-07 Impact factor: 11.528
Authors: Esther Ocaña; Luis Delgado-Pérez; Antonio Campos-Caro; Juan Muñóz; Antonio Paz; Rafael Franco; José A Brieva Journal: Haematologica Date: 2007-03 Impact factor: 9.941
Authors: Femke Van Bockstaele; Valerie Pede; Ann Janssens; Filip Callewaert; Fritz Offner; Bruno Verhasselt; Jan Philippé Journal: Clin Chem Date: 2006-12-07 Impact factor: 8.327
Authors: M Bilban; D Heintel; T Scharl; T Woelfel; M M Auer; E Porpaczy; B Kainz; A Kröber; V J Carey; M Shehata; C Zielinski; W Pickl; S Stilgenbauer; A Gaiger; O Wagner; U Jäger Journal: Leukemia Date: 2006-06 Impact factor: 11.528
Authors: Tanisha A Jackson; Christopher L Haga; Götz R A Ehrhardt; Randall S Davis; Max D Cooper Journal: J Immunol Date: 2010-11-10 Impact factor: 5.422
Authors: Valerie Pede; Ans Rombout; Jolien Vermeire; Evelien Naessens; Pieter Mestdagh; Nore Robberecht; Hanne Vanderstraeten; Nadine Van Roy; Jo Vandesompele; Frank Speleman; Jan Philippé; Bruno Verhasselt Journal: PLoS One Date: 2013-04-01 Impact factor: 3.240